G. Caleb Alexander

658 total citations
11 papers, 391 citations indexed

About

G. Caleb Alexander is a scholar working on Economics and Econometrics, Immunology and Physiology. According to data from OpenAlex, G. Caleb Alexander has authored 11 papers receiving a total of 391 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Economics and Econometrics, 5 papers in Immunology and 2 papers in Physiology. Recurrent topics in G. Caleb Alexander's work include Health Systems, Economic Evaluations, Quality of Life (9 papers), Pharmaceutical Economics and Policy (8 papers) and Biosimilars and Bioanalytical Methods (5 papers). G. Caleb Alexander is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (9 papers), Pharmaceutical Economics and Policy (8 papers) and Biosimilars and Bioanalytical Methods (5 papers). G. Caleb Alexander collaborates with scholars based in United States, United Kingdom and Canada. G. Caleb Alexander's co-authors include Thomas J. Moore, Gerard F. Anderson, Hanzhe Zhang, James Heyward, Shweta Mital, David S. Knopman, Hai V. Nguyen, Kenneth M. Shermock, Dora H. Lin and K. OGASAWARA and has published in prestigious journals such as PLoS ONE, Neurology and JAMA Internal Medicine.

In The Last Decade

G. Caleb Alexander

10 papers receiving 381 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
G. Caleb Alexander United States 8 169 57 57 54 45 11 391
Marisa Papaluca‐Amati Netherlands 10 75 0.4× 47 0.8× 87 1.5× 33 0.6× 53 1.2× 11 395
Hanzhe Zhang China 5 81 0.5× 30 0.5× 33 0.6× 33 0.6× 53 1.2× 8 273
Daniel Tobias Michaeli Germany 14 291 1.7× 30 0.5× 44 0.8× 61 1.1× 47 1.0× 48 550
Cathy Anne Pinto United States 11 159 0.9× 25 0.4× 35 0.6× 35 0.6× 22 0.5× 29 509
Thomas Michaeli Germany 13 240 1.4× 21 0.4× 36 0.6× 51 0.9× 45 1.0× 39 467
Ashlyn Pinto Canada 5 262 1.6× 31 0.5× 59 1.0× 30 0.6× 26 0.6× 10 430
Jacqueline Corrigan‐Curay United States 9 148 0.9× 45 0.8× 106 1.9× 60 1.1× 135 3.0× 13 616
Elita Poplavska Latvia 4 266 1.6× 32 0.6× 54 0.9× 37 0.7× 26 0.6× 12 435
Zhimin Yang China 11 74 0.4× 38 0.7× 22 0.4× 51 0.9× 72 1.6× 25 397
Kelly Plueschke Netherlands 7 140 0.8× 25 0.4× 56 1.0× 28 0.5× 22 0.5× 12 279

Countries citing papers authored by G. Caleb Alexander

Since Specialization
Citations

This map shows the geographic impact of G. Caleb Alexander's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by G. Caleb Alexander with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites G. Caleb Alexander more than expected).

Fields of papers citing papers by G. Caleb Alexander

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by G. Caleb Alexander. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by G. Caleb Alexander. The network helps show where G. Caleb Alexander may publish in the future.

Co-authorship network of co-authors of G. Caleb Alexander

This figure shows the co-authorship network connecting the top 25 collaborators of G. Caleb Alexander. A scholar is included among the top collaborators of G. Caleb Alexander based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with G. Caleb Alexander. G. Caleb Alexander is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
1.
Kim, Minji, Michael Schweitzer, Ji Soo Kim, G. Caleb Alexander, & Hemalkumar B. Mehta. (2025). Use of Glucagon-Like Peptide-1 Agonists Among Individuals Undergoing Bariatric Surgery in the US. JAMA Surgery. 160(10). 1058–1058.
2.
Nguyen, Hai V., Shweta Mital, David S. Knopman, & G. Caleb Alexander. (2024). Cost-Effectiveness of Lecanemab for Individuals With Early-Stage Alzheimer Disease. Neurology. 102(7). e209218–e209218. 28 indexed citations
3.
Moore, Thomas J., et al.. (2023). Inclusion of Participants with CKD and Other Kidney-Related Considerations during Clinical Drug Development. Clinical Journal of the American Society of Nephrology. 18(4). 455–464. 7 indexed citations
4.
Sen, Aditi P., et al.. (2021). Characteristics of Copayment Offsets for Prescription Drugs in the United States. JAMA Internal Medicine. 181(6). 758–758. 12 indexed citations
5.
Moore, Thomas J., James Heyward, Gerard F. Anderson, & G. Caleb Alexander. (2020). Variation in the estimated costs of pivotal clinical benefit trials supporting the US approval of new therapeutic agents, 2015–2017: a cross-sectional study. BMJ Open. 10(6). e038863–e038863. 55 indexed citations
6.
Moore, Thomas J., et al.. (2020). Assessment of Availability, Clinical Testing, and US Food and Drug Administration Review of Biosimilar Biologic Products. JAMA Internal Medicine. 181(1). 52–52. 31 indexed citations
7.
Hsiue, Emily Han-Chung, Thomas J. Moore, & G. Caleb Alexander. (2020). Estimated costs of pivotal trials for U.S. Food and Drug Administration–approved cancer drugs, 2015–2017. Clinical Trials. 17(2). 119–125. 9 indexed citations
8.
Qiao, Yao, G. Caleb Alexander, & Thomas J. Moore. (2019). Globalization of clinical trials: Variation in estimated regional costs of pivotal trials, 2015–2016. Clinical Trials. 16(3). 329–333. 10 indexed citations
9.
Murimi, Irene B., Jeromie Ballreich, Marissa J. Seamans, & G. Caleb Alexander. (2019). Association between US Pharmacopeia (USP) monograph standards, generic entry and prescription drug costs. PLoS ONE. 14(11). e0225109–e0225109. 7 indexed citations
10.
Moore, Thomas J., Hanzhe Zhang, Gerard F. Anderson, & G. Caleb Alexander. (2018). Estimated Costs of Pivotal Trials for Novel Therapeutic Agents Approved by the US Food and Drug Administration, 2015-2016. JAMA Internal Medicine. 178(11). 1451–1451. 222 indexed citations
11.
OGASAWARA, K., Christopher D. Breder, Dora H. Lin, & G. Caleb Alexander. (2017). Exposure– and Dose–response Analyses in Dose Selection and Labeling of FDA-approved Biologics. Clinical Therapeutics. 40(1). 95–102.e2. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Marisa Papaluca‐Amati Breakdown of academic impact, for papers by Hanzhe Zhang Breakdown of academic impact, for papers by Daniel Tobias Michaeli Breakdown of academic impact, for papers by Cathy Anne Pinto Breakdown of academic impact, for papers by Thomas Michaeli Breakdown of academic impact, for papers by Ashlyn Pinto Breakdown of academic impact, for papers by Jacqueline Corrigan‐Curay Breakdown of academic impact, for papers by Elita Poplavska Breakdown of academic impact, for papers by Zhimin Yang Breakdown of academic impact, for papers by Kelly Plueschke
Rankless by CCL
2026